Stability Indicating HPLC Method for Quantification of Solifenacin Succinate & Tamsulosin Hydrochloride along with Its Impurities in Tablet Dosage Form

A novel stability-indicating RP-HPLC method was developed and validated for simultaneous determination of Solifenacin Succinate & Tamsulosin Hydrochloride and its impurities in tablet dosage form. The method was developed using L1 column with gradient using the mobile phase consist of solvent-A (pH = 6.6, phosphate buffer + 0.5% Triethylamine) and solvent-B (90% Acetonitrile). The eluted compounds were monitored at 225 nm. Solifenacin Succinate & Tamsulosin Hydrochloride was subjected to oxidative, acid, base, hydrolytic, thermal and photolytic stress conditions. The developed method was validated as per ICH guidelines with respect to specificity, linearity, limit of detection, limit of quantitation, accuracy, precision and robustness. The limit of quantification results was ranged from 0.135 - 0.221 μg/mL for Solifenacin Succinate impurities and 0.043 - 0.090 μg/mL for Tamsulosin Hydrochloride impurities. This method is suitable for the estimation of impurities and assay of Solifenacin Succinate & Tamsulosin Hydrochloride in tablets dosage form.

[1]  C. Ivanescu,et al.  Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia , 2015, BMC Urology.

[2]  B. Z. Awen,et al.  Bioanalytical method for quantification of Solifenacin in rat plasma by LC-MS/MS and its application to pharmacokinetic study , 2014, Journal of Analytical Science and Technology.

[3]  S. Puttagunta,et al.  Analytical Method Development and Validation of Solifenacin in Pharmaceutical Dosage Forms by RP-HPLC , 2014 .

[4]  C. Thota,et al.  A RAPID RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTITATIVE ESTIMATION OF SOLIFENACIN SUCCINATE IN TABLETS , 2014 .

[5]  M. Priya,et al.  IMPURITY METHOD DEVELOPMENT AND VALIDATION OF TAMSULOSIN HYDROCHLORIDE BY USING RP-HPLC , 2014 .

[6]  D. Gowrisankar,et al.  RP-HPLC METHOD FOR THE ESTIMATION OF TAMSULOSIN AND SOLIFENACIN IN BULK AND ITS DOSAGE FORMS , 2013 .

[7]  C. Sekaran,et al.  RP-HPLC METHOD FOR THE ESTIMATION OF TAMSULOSIN IN BULK AND CAPSULES , 2013 .

[8]  C. Rambabu,et al.  Development and Validation of a Specific Stability Indicating High Performance Liquid Chromatographic Methods for Related Compounds and Assay of Solifenacin Succinate , 2013 .

[9]  M. Janardhan,et al.  DEVELOPMENT AND VALIDATION OF STABILITY-INDICATING RP-HPLC METHOD FOR ESTIMATION OF TAMSULOSIN HCL PELLETS , 2012 .

[10]  S. Jain,et al.  Stability-indicating HPLC Assay Method and Degradation Profile of Tamsulosin , 2012 .

[11]  C. Ramakrishna,et al.  Novel Spectroscopic Methods for the Determination of Tamsulosin in Bulk and Capsules , 2012 .

[12]  Sung Yul Park,et al.  Effects of Tamsulosin, Solifenacin, and Combination Therapy for the Treatment of Ureteral Stent Related Discomforts , 2011, Korean journal of urology.

[13]  Syed sajjad Hussen,et al.  Development & validation of stability indicating HPLC method for determination of Solifenacin in bulk formulations , 2011 .

[14]  T. Sudha,et al.  A VALIDATED RP­HPLC METHOD FOR THE DETERMINATION OF IMPURITIES IN TAMSULOSIN HCL , 2011 .

[15]  N. Rao,et al.  A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography. , 2010, Journal of chromatographic science.

[16]  T. Iwatsubo,et al.  Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[17]  N. V. Ramakrishna,et al.  Rapid, simple and highly sensitive LC-ESI-MS/MS method for the quantification of tamsulosin in human plasma. , 2005, Biomedical chromatography : BMC.

[18]  D. Faulds,et al.  Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. , 2002, Drugs & aging.